Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Haisco Partners with AbbVie to Develop Novel Medicines for Pain in a ~$745M Deal
Haisco Pharma signed an exclusive licensing agreement with AbbVie to develop, manufacture and commercialize novel pain medicines outside China, Hong Kong and Macau. The deal provides Haisco with a $30 million upfront payment and up to $715 million in development, regulatory and commercial milestones, plus tiered royalties on future sales. AbbVie will contribute its global development expertise while Haisco adds several pain‑related compounds ranging from preclinical to Phase I to its pipeline. The partnership expands Haisco’s international footprint and diversifies AbbVie’s pain‑management portfolio.
Parents Underestimate Deadly Risk of Vaccine‑preventable Diseases
https://youtu.be/sLyGdEtRPyQ?si=HhO95z45Mz20D6kp We never imagine that our children could suffer or die from a vaccine-preventable disease.
STAT+: Allogene Therapeutics’ CAR-T Treatment Eliminates Residual Cancer Cells in B-Cell Lymphoma Patients
Allogene Therapeutics reported that its off‑the‑shelf CAR‑T therapy, cema‑cel, eliminated residual cancer cells in B‑cell lymphoma patients at three times the rate of standard care, meeting the interim goal of its Phase 3 trial. In the interim analysis, 58% of treated...
Cartherics and Catalent Expand Commercial License Agreement
Cartherics and Catalent have signed an amended commercial license agreement granting Cartherics access to Catalent's cGMP‑compliant iPSC line for manufacturing its CAR‑NK cell therapies, including lead candidate CTH‑401. The partnership enables Cartherics to use the line for development, clinical trials,...
NICE Update Doubles Eligible Patients for AZ's Lokelma
NICE’s draft guidance doubles the number of patients in England and Wales who can receive AstraZeneca’s Lokelma for hyperkalaemia. The eligibility threshold was lowered from a serum potassium level of 6.0 mmol/L to 5.5 mmol/L, and the specialist‑only initiation rule was removed....
Predict, Prevent, Perform: The AI Evolution of Denials Management
Healthcare providers are grappling with denial rates near 12% in 2025, translating into millions of dollars of delayed revenue per percentage point. Legacy manual processes can’t keep pace with AI‑driven payer adjudication that rejects claims for minor errors. Providers are...
The Evolution of Amazon’s Healthcare Strategy: From Primary Care to Care Orchestration
Amazon Health Services launched the Health Benefits Connector (HBC) in early 2024 and expanded it in 2026 to include AI‑driven nutrition therapy from Berry Street and precision sleep diagnostics via Dreem Health. The platform verifies insurance eligibility in real time, triages patients...
Constellation Kidney Group Expands KidneyOne™, Its Integrated Platform for Kidney Care Providers, with Launch of RCM Intelligence
Constellation Kidney Group (CKG) announced the launch of RCM Intelligence, an analytics add‑on to its KidneyOne™ platform. The new capability deepens the CKG Intelligence data and AI layer, turning raw dialysis billing information into actionable operational metrics. RCM Intelligence is...
Fee-for-Service Payment Approach Creates Obstacles to AI Adoption by Physicians
A new NEJM Catalyst report finds that the fee‑for‑service (FFS) reimbursement model discourages physicians from adopting clinical AI because efficiency gains shrink billable time. When AI halves a visit, doctors see a proportional drop in revenue, creating a misaligned incentive....
Feature: Why Quality of Care Still Depends on Robust Print Security
HP highlights that printer downtime during cyber incidents can cripple NHS clinical workflows, as seen in the Synnovis attack that delayed over 11,000 appointments. Because many trusts acquire printers piecemeal, firmware and security settings become inconsistent, making devices easy entry...
Public Health Meets the Care Economy: Care As Infrastructure
In Part 2 of her two‑part miniseries, Katie Schenk argues that public‑health agencies treat caregiving as an individual issue rather than essential infrastructure, exposing a structural mismatch that fuels inequity and attrition. She details how pandemic‑era successes turned into political liabilities,...
Digital Tool Aims to Promote Later-Life Bladder Health
Researchers from the University of Manchester, Lithuanian Sports University and the University of Vic have launched KOKU Bladder, a digital platform that blends evidence‑based education, pelvic‑floor muscle training, behavior‑change techniques and gamification to support bladder health in adults 50+. The...
Rethinking the Role of Family Physicians Vs. Specialists
Ronald L. Lindsay argues that family physicians are not the health‑care backbone, citing limited pediatric training, insurer cost preferences, and outcome data that favor specialists. He highlights that pediatric nurse practitioners, OB/GYNs, hospitalists, and urgent‑care clinicians deliver higher‑value care at...
Radiology Partners Reportedly Eyeing International Expansion
Radiology Partners, the United States' largest radiology group, is reportedly pursuing an acquisition of Australia’s I‑MED Radiology Network, which operates over 240 clinics and generated roughly AU$176 million (about US$116 million) in adjusted earnings last year. The move follows RP’s earlier bid...
Scientists Are Trying to Build a Vaccine that Works Against Almost Any Respiratory Pathogen — Here's How Close They Are.
Scientists at Stanford have engineered an experimental nasal spray that activates the lungs' innate immune system rather than targeting specific antigens. In mouse studies the spray slashed viral loads by roughly 700‑fold and bacterial counts by 200‑fold, while also dampening...
McAvoy Go-Ahead for £65m Bradford Hospital Overhaul
The UK government has approved a £65 million (≈ $82 million) overhaul of Bradford District Care NHS Foundation Trust’s mental health facilities, with £50 million (≈ $63.5 million) coming from public funds. McAvoy will build a modular two‑storey ward block and refurbish two existing wards to...
LUT014 Shows Promise for RASi‑Induced Skin Rash
*Disclaimer : the company developing LUT014 is a Pontifax portfolio company.* Mechanistically LUT014 should be effective in RASi induced-rash as it was designed to activate RAS signaling in the skin so using it topically could de-couple RAS inhibition in the tumor...
Ideaya’s Uveal Melanoma Drug Exceeds Success Benchmark in Late-Stage Trial
Ideaya BioSciences reported that its late‑stage drug for uveal melanoma met its pre‑specified success benchmark, achieving a 27% overall response rate versus the 20% target. The trial also demonstrated a manageable safety profile, reinforcing confidence in the therapy’s risk‑benefit balance....
Association Between Cumulative Changes of the C-Reactive Protein-Triglyceride Glucose Index and the Incidence of Rapid Kidney Function Decline: A Nationwide...
A nationwide prospective cohort study of 6,888 Chinese adults aged 45 and older found that higher cumulative C‑reactive protein‑triglyceride glucose index (cuCTI) is linked to rapid kidney function decline (RKFD). Each one‑unit increase in cuCTI raised the odds of RKFD...
Inflammatory Dietary Scores and Their Association with Clinical Outcomes in Coronary Heart Disease
A retrospective cohort of 500 angiographically confirmed coronary heart disease patients followed for a median of 38 months found that higher Dietary Inflammatory Index (DII) scores were linked to significantly increased risk of major adverse cardiovascular events (MACE), all‑cause mortality,...
Dietary Intake, Nutritional Status and Healthcare Characteristics of Mothers and Newborn Infants in a Prospective Cohort Study (CHAMP) From a...
The CHAMP cohort study reports baseline data from 70 mothers and 72 newborns in rural Swat, Pakistan, a region plagued by chronic malnutrition. Households earned roughly $106 per month, well below the national minimum wage, and most parents lacked formal...
Microbiota-Metabolites Interaction Associated with Glycemic Improvement Following a Dietary Herbal Intervention in Type 2 Diabetes
The study evaluated QingYun7 (QY7), a standardized dietary herbal blend, in diabetic rats and a prospective cohort of 385 type‑2 diabetes patients. QY7 significantly lowered fasting, random and post‑prandial glucose while reshaping the gut microbiome and serum metabolite profile. Fecal...
Fasting Blood Glucose to High-Density Lipoprotein Cholesterol Ratio and MASLD Risk: Non-Linear Association and BMI Mediation in Non-Diabetic Adults
A large cross‑sectional analysis of 13,682 non‑diabetic Japanese adults found that the fasting blood glucose‑to‑HDL‑C ratio (GHR) is strongly linked to metabolic dysfunction‑associated steatotic liver disease (MASLD). After adjusting for multiple confounders, each 1‑unit rise in GHR increased MASLD odds...
Structural Elucidation and Antidiabetic Activity of Polysaccharides From the Parasitic Plant Orobanche Cumana
Researchers isolated three polysaccharide fractions from the parasitic plant Orobanche cumana and identified the alkaline‑extracted fraction OCP‑3 as a low‑molecular‑weight rhamnogalacturonan‑I‑rich polysaccharide. OCP‑3 showed strong antioxidant activity and inhibited key carbohydrate‑digesting enzymes, with IC₅₀ values of 98.5 µg mL⁻¹ for α‑amylase and...
High‑dose GLP‑1s Raise Optic Nerve Risk; Titrate Carefully
Patients are not asking if GLP-1s are right for them. They are asking how much you charge for tirzepatide. Shiv K. Goel breaks down what physicians need to know about oral Wegovy. Pharmacovigilance data: Wegovy carries nearly five times higher...
BIO Coffee Chat Explores Venture Philanthropy
The Biotechnology Innovation Organization (BIO) hosted a Patient Advocacy Coffee Chat highlighting the growing influence of venture philanthropy in biotech. Patient groups are now acting as investors, using capital and disease expertise to de‑risk early‑stage programs and guide trial design....
EU Launches PsyPal Project to Test Psychedelic Therapy in Palliative Care
The European Union has kicked off the PsyPal project, a EU‑funded clinical initiative to evaluate psychedelic therapy for psychological distress in palliative‑care patients. The launch event was held on 13 April 2026 at the Directorate‑General for Health and Food Safety, marking the...
GSK’s Mo-Rez ADC Shrinks Ovarian and Endometrial Tumors in 62‑67% of Patients
GSK announced that its antibody‑drug conjugate Mo‑Rez reduced or eliminated tumors in 62% of ovarian‑cancer patients and 67% of endometrial‑cancer patients who had failed chemotherapy. The early‑stage data, gathered from 224 participants, will fast‑track the drug into five late‑stage studies...
K-12 Telehealth Provider Faces Uncertain Future as Funding Dries Up
Hazel Health, once the nation’s largest K‑12 telehealth provider, has slashed 135 jobs, reducing its workforce to roughly 500 employees. The company lost its $28 million Los Angeles County contract and saw Chicago’s agreement shortened, while several districts are letting contracts...
This Method to Reverse Cellular Aging Is About to Be Tested in Humans
Researchers at the Whitehead Institute have engineered a three‑gene cocktail that partially reprograms aged retinal nerve cells, reversing age‑related damage in mouse eyes. The breakthrough underpins Life Biosciences' first human clinical trial, which will deliver the Yamanaka factors—minus the oncogenic...
Prior Authorization Reform Is Here — And It Could Change How Millions Get Care
CMS has rolled out its first major prior‑authorization reform in decades, mandating 72‑hour turnaround for urgent and seven‑day for standard non‑drug requests in Medicare Advantage, Medicaid, CHIP and ACA plans. A new proposal extends those deadlines to prescription drugs, requiring...
9 Questions Radiology Practices Should Ask when Pursuing ‘Disruptive Innovation’
Kaihan Krippendorff, a strategist and founder of Outthinker Networks, delivered the opening keynote at the Radiology Business Management Association’s annual meeting, unveiling nine "P"‑based questions for radiology practices seeking disruptive innovation. He framed the discussion around "fourth options"—new market segments...
Hers Disrupts Women’s Primary Care with Direct‑to‑Consumer Telehealth Platform
Hers, the women‑focused arm of the Hims brand, provides a full‑service telehealth experience that lets users complete a diagnostic quiz, receive a provider review and have prescription meds delivered to their door. The model challenges traditional primary‑care clinics by turning...
Medicare IRMAA Surcharges for 2026 Trigger Appeals Wave Among Seniors
The Social Security Administration will apply 2026 Income‑Related Monthly Adjustment Amount (IRMAA) surcharges based on 2024 tax returns, potentially raising premiums for high‑income retirees. Seniors have 60 days to appeal a surcharge they deem unfair, using Form SSA‑44 and a...
Dana‑Farber CEO Outlines Ambitious Hospital Transformation Plan
Dana‑Farber Cancer Institute's chief executive announced a multi‑year construction and service redesign that will break ground in late 2026, finish the new hospital by the end of 2030 and move patients in early 2031. The plan adds an observation unit,...
Regular Sleep Reduces Risk of Major Cardiac Events
Consistent sleep patterns may be essential for cardiovascular health 🫀💤 This new study investigated sleep habits and cardiovascular events in over 3,000 individuals 🔍 Participants were followed for ~10 years or until experienced a MACE (acute myocardial infarction, unstable angina, stroke, heart...
Allogeneic CAR‑T Achieves 42% MRD Boost, Safe Profile
Allogene $ALLO cema-cel interim ALPHA3 results just reported: B-cell lymphoma MRD negativity: cema-cel 58% vs observation 16% A 42% absolute difference in MRD clearance is better than expected. Clean safety profile, too. Allogeneic CAR-T may have found its role. Nice...
Prediction: Buying This Biotech Stock Today Could Set You Up for Life
Mirum Pharmaceuticals (NASDAQ:MIRM) has surged more than 120% over the past year, driven by strong sales of its rare‑disease therapies. In Q4 2025 the company posted a 50% jump in net product revenue, with Livmarli alone generating $360 million. Mirum expects four...
Eliminating Cancer Could Add $197 Trillion to Economy
New @nberpubs: "The Economic Value of Eliminating Cancer" https://t.co/BJtM1578oY "Eliminating cancer mortality generates $197 trillion in economic benefits over 35 years, corresponding to approximately $16,282 per American per year, or $41,684 per American household per year" https://t.co/QQ3KYmQezj
Flavored E‑cig Ban Cuts Vaping Interest, Boosts Smoking Demand
New @nberpubs: "Consumer Tobacco Product Choices in China: The Impact of a Ban on Flavored E-Cigarettes" https://t.co/GeojsfqozA "a ban of flavored e-cigarettes decreases stated preferences for e-cigarettes but also has the unintended consequence to increase stated preferences for cigarettes" 😲
GLP-1 Tablets and the Shift in Discourse About Obesity
Foundayo, the first oral non‑peptide GLP‑1 tablet, received FDA approval last week, marking a new chapter in obesity treatment and intensifying competition with Novo Nordisk’s Wegovy pill. The launch coincides with a measurable shift in media coverage: mentions of obesity...
Spyre's SPY001 Achieves 40% Remission in UC Trial
Spyre $SYRE just reported SPY001 (long-acting alpha4beta7 antibody) ulcerative colitis induction data. Here's the efficacy chart, notable for a 40% clinical remission rate at week 12, albeit with small number of patients. https://t.co/aEoLWPRjEL
ALLO's Alpha-3 DLBCL Data Set to Spark Pre‑Market Move
Key $ALLO catalyst coming pre market today, with first data from cema-cel's Alpha-3 study in DLBCL consolidation. What to look for: https://t.co/a19BVEppqP
Almirall and Barcelona Supercomputing Center Expand Their Collaboration to Accelerate Innovation in Medical Dermatology
Almirall, a global medical dermatology company, has expanded its partnership with the Barcelona Supercomputing Center (BSC) under the BSC Connects program. The new framework, running through 2026, gives Almirall access to BSC’s AI and high‑performance computing resources, including the MareNostrum 5...
Darovasertib Shows Promise in Optimum-02 Uveal Melanoma Trial
$IDYA darovasertib data from registrational Optimum-02 trial in uveal melanoma are out. What to look for: https://t.co/1LQa0X6xJa
A New Wave of Immunotherapy Is Eliminating Cancers
Immunotherapy, especially checkpoint inhibitors like dostarlimab, is delivering unprecedented tumor regressions, with recent trials reporting complete remission in 84% of participants. The approach offers non‑surgical, low‑toxicity alternatives, as illustrated by patients such as Maureen Sideris whose esophageal cancer vanished after...
Rising Therapy-Related Leukemia Rates Signal New Testing Demands for Clinical Labs
Long‑term data from Japan’s Osaka Cancer Registry show therapy‑related acute myeloid leukemia (tAML) rates climbing from 0.13 to 0.36 cases per 100,000 between 1990 and 2020, now representing 6.5% of all AML diagnoses. The proportion of tAML within AML cases...
A Paediatrician’s Fight for ORS Triggers a Larger Debate in the Fraternity
Dr. Sivaranjani Santosh, a pediatrician who previously pushed the FSSAI to prohibit the use of the “ORS” label on non‑pharmaceutical drinks, has resigned from the Indian Academy of Pediatrics (IAP) citing disagreements over the academy’s recent position on ORS and...
How Claude Mythos Preview Found Thousands of Zero-Day Vulnerabilities and Why the Health Tech Sector’s Absence From Project Glasswing Should...
On April 7, 2026 Anthropic unveiled Claude Mythos Preview, an AI model that autonomously discovered thousands of zero‑day vulnerabilities across major operating systems and browsers. The company kept the model private and launched Project Glasswing, a defensive coalition of 40+...
Telix and Regeneron Sign $4.3bn Deal to Co-Develop Radiopharmaceutical Therapies
Telix and Regeneron Pharmaceuticals have signed a partnership valued at up to $4.3 billion to co‑develop radiopharmaceutical therapies for solid tumours. Regeneron will pay $40 million upfront for access to Telix’s manufacturing platform and can expand to four additional programmes, while Telix...